Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
89% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 382.22   Max: No Debt
Current: No Debt

Equity to Asset 0.82
ABMD's Equity to Asset is ranked higher than
86% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABMD: 0.82 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.93
Current: 0.82

0.79
0.93
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
87% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 117.58 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 16.83
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 4.55
ABMD's Operating margin (%) is ranked higher than
70% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. ABMD: 4.55 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 4.55

-111.48
10.46
Net-margin (%) 4.00
ABMD's Net-margin (%) is ranked higher than
72% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. ABMD: 4.00 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 4

-84.54
9.5
ROE (%) 4.37
ABMD's ROE (%) is ranked higher than
71% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. ABMD: 4.37 )
ABMD' s 10-Year ROE (%) Range
Min: -43.73   Max: 10.95
Current: 4.37

-43.73
10.95
ROA (%) 3.58
ABMD's ROA (%) is ranked higher than
74% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. ABMD: 3.58 )
ABMD' s 10-Year ROA (%) Range
Min: -37.5   Max: 8.83
Current: 3.58

-37.5
8.83
ROC (Joel Greenblatt) (%) 46.81
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. ABMD: 46.81 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -318.99   Max: 85.31
Current: 46.81

-318.99
85.31
Revenue Growth (%) 17.50
ABMD's Revenue Growth (%) is ranked higher than
92% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (%) Range
Min: -7.2   Max: 25.1
Current: 17.5

-7.2
25.1
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ABMD Guru Trades in Q2 2013

Jim Simons 132,223 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Pioneer Investments Sold Out
Steven Cohen 2,300 sh (-87.88%)
» More
Q3 2013

ABMD Guru Trades in Q3 2013

Paul Tudor Jones 16,000 sh (New)
Steven Cohen 15,457 sh (+572.04%)
Jim Simons 260,523 sh (+97.03%)
PRIMECAP Management 5,751,990 sh (unchged)
» More
Q4 2013

ABMD Guru Trades in Q4 2013

PRIMECAP Management 5,751,990 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 79,323 sh (-69.55%)
» More
Q1 2014

ABMD Guru Trades in Q1 2014

Steven Cohen 11,972 sh (New)
Joel Greenblatt 25,692 sh (New)
Paul Tudor Jones 11,200 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 New Buy0.01%$25.6 - $30.03 $ 26.29-5%25692
PRIMECAP Management 2011-06-30 Add 28.42%0.02%$14.65 - $18.94 $ 26.2956%3772973
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 142.10
ABMD's P/E(ttm) is ranked higher than
68% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 67.60 vs. ABMD: 142.10 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 142.1

36.46
946.92
P/B 6.22
ABMD's P/B is ranked higher than
54% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. ABMD: 6.22 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 7.69
Current: 6.22

1.58
7.69
P/S 5.88
ABMD's P/S is ranked higher than
59% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. ABMD: 5.88 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 10.62
Current: 5.88

2.38
10.62
PFCF 53.65
ABMD's PFCF is ranked higher than
81% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 53.65 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 53.65

23.56
2462
EV-to-EBIT 116.36
ABMD's EV-to-EBIT is ranked higher than
68% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. ABMD: 116.36 )
ABMD' s 10-Year EV-to-EBIT Range
Min: 27   Max: 694.7
Current: 116.36

27
694.7
Current Ratio 3.88
ABMD's Current Ratio is ranked higher than
79% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ABMD: 3.88 )
ABMD' s 10-Year Current Ratio Range
Min: 3.67   Max: 14.38
Current: 3.88

3.67
14.38
Quick Ratio 3.42
ABMD's Quick Ratio is ranked higher than
81% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. ABMD: 3.42 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.78   Max: 13.94
Current: 3.42

2.78
13.94

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.55
ABMD's Price/Net Cash is ranked higher than
84% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 26.55 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.71   Max: 31.29
Current: 26.55

1.71
31.29
Price/Net Current Asset Value 16.13
ABMD's Price/Net Current Asset Value is ranked higher than
81% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 16.13 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.54   Max: 58.18
Current: 16.13

1.54
58.18
Price/Tangible Book 8.04
ABMD's Price/Tangible Book is ranked higher than
60% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. ABMD: 8.04 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1.34   Max: 9.73
Current: 8.04

1.34
9.73
Price/DCF (Projected) 6.57
ABMD's Price/DCF (Projected) is ranked higher than
82% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABMD: 6.57 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 6.51   Max: 41.45
Current: 6.57

6.51
41.45
Price/Median PS Value 0.96
ABMD's Price/Median PS Value is ranked higher than
82% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ABMD: 0.96 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 2.29
Current: 0.96

0.38
2.29
Price/Graham Number 7.13
ABMD's Price/Graham Number is ranked higher than
71% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9.06 vs. ABMD: 7.13 )
ABMD' s 10-Year Price/Graham Number Range
Min: 3.89   Max: 15.85
Current: 7.13

3.89
15.85
Earnings Yield (Greenblatt) 0.90
ABMD's Earnings Yield (Greenblatt) is ranked lower than
56% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. ABMD: 0.90 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.9

0.1
3.7
Forward Rate of Return (Yacktman) -0.47
ABMD's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. ABMD: -0.47 )
ABMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.1   Max: -0.5
Current: -0.47

-4.1
-0.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany
Abiomed, Inc., is a Delaware corporation. The Company is a provider of mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company's Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. It manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company's AbioCor Implantable Replacement Heart is the first completely self-contained artificial heart, designed to sustain the body's circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Its main competitors are Getinge, Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, CircuLite, Inc., Terumo Heart, Inc. and CardiacAssist Inc. The Company is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 
Trade Setups for May 17, 2010 May 17 2010 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 05 2010 

More From Other Websites
Abiomed First Quarter Fiscal 2015 Earnings and Conference Call Notification Jul 16 2014
ABIOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jul 07 2014
ABIOMED Acquires Germany's Medical Device Maker Jul 02 2014
Abiomed Announces Acquisition of ECP to Broaden and Strengthen Existing Intellectual Property and... Jul 01 2014
ABIOMED INC Files SEC form 8-K, Other Events Jun 11 2014
ABIOMED Impella Platform Crosses 20K Mark Jun 05 2014
ABIOMED INC Financials Jun 04 2014
Abiomed, Salem State University and North Shore Community College Host First-Ever Life Sciences... Jun 04 2014
Abiomed to Present at the William Blair Growth Stock Conference Jun 04 2014
Abiomed surpasses 20,000 U.S. Impella patients Jun 03 2014
Abiomed surpasses 20,000 U.S. Impella patients Jun 03 2014
Abiomed Surpasses 20,000 Impella Patients in the United States Jun 03 2014
Insider Trading Alert - WPX, ANDE And ABMD Traded By Insiders May 29 2014
Abiomed discloses subpoena received in April from Boston DHHS office May 28 2014
ABIOMED INC Files SEC form 10-K, Annual Report May 28 2014
Abiomed to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014
Abiomed Receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP Study May 21 2014
ABIOMED INC Files SEC form 8-K, Change in Directors or Principal Officers May 20 2014
Insider Trading Alert - SAM, ABMD And GAS Traded By Insiders May 19 2014
Abiomed's Impella(R) Technology Showcased at EuroPCR 2014 May 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide